Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX

Key Points

• Dimensional Fund Advisors increased its Bicara Therapeutics stake by 166.9% in the first quarter, bringing its holdings to 109,261 shares valued at approximately $2.17 million. Several other institutional investors also expanded their positions.
• Analyst sentiment remains broadly positive, with Bicara carrying a “Moderate Buy” consensus rating and an average price target of $32.73, despite ratings ranging from Sell to Strong Buy.
• BCAX recently traded at $23.63 and fell 4.1%; the company reported a quarterly loss of $0.82 per share, in line with estimates. Investors are focused on clinical progress, including planned 2026 enrollment for the pivotal fic­erafusp alfa study, while insider share sales could weigh on sentiment.

Dimensional Fund Advisors LP grew its holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 166.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 109,261 shares of the company's stock after purchasing an additional 68,327 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.17% of Bicara Therapeutics worth $2,170,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of BCAX. Legal & General Group Plc grew its holdings in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock valued at $29,000 after buying an additional 1,233 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock worth $44,000 after buying an additional 3,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Bicara Therapeutics in the fourth quarter worth $45,000. Larson Financial Group LLC raised its holdings in shares of Bicara Therapeutics by 1,015.5% in the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock worth $62,000 after acquiring an additional 3,595 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its position in shares of Bicara Therapeutics by 385.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company's stock valued at $97,000 after acquiring an additional 4,585 shares in the last quarter.

Analyst Upgrades and Downgrades

BCAX has been the subject of a number of recent research reports. Guggenheim began coverage on Bicara Therapeutics in a research report on Monday, May 11th. They set a "buy" rating and a $42.00 price objective for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Bicara Therapeutics in a report on Monday, July 6th. Wall Street Zen raised shares of Bicara Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Sunday, May 24th. Mizuho lifted their price target on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the stock a "neutral" rating in a report on Wednesday. Finally, The Goldman Sachs Group boosted their price objective on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the company a "neutral" rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $32.73.

Bicara Therapeutics Trading Down 4.1%

Bicara Therapeutics stock opened at $23.63 on Friday. The firm has a market capitalization of $1.56 billion, a P/E ratio of -7.62 and a beta of -0.75. The stock has a fifty day moving average price of $26.06 and a 200 day moving average price of $21.79. Bicara Therapeutics Inc. has a 52 week low of $10.30 and a 52 week high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.82). As a group, equities analysts predict that Bicara Therapeutics Inc. will post -3.5 EPS for the current year.

Key Stories Impacting Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Management said enrollment for the pivotal study of ficerafusp alfa remains on track for 2026. Progress toward this milestone could provide an important catalyst for the clinical-stage biotechnology company. Bicara Therapeutics cancer study remains on track
• Positive Sentiment: Analysts raised several price targets following the quarterly results. BTIG increased its target from $28 to $39 and retained a Buy rating, while Morgan Stanley raised its target to $39 with an Overweight rating. The reported consensus view remains Moderately Buy-rated, with an average target near $32.73. Analysts raise Bicara forecasts
• Neutral Sentiment: Bicara reported a second-quarter loss of $0.82 per share, matching the consensus estimate. The result did not provide a major earnings surprise, leaving clinical execution and upcoming trial milestones as the primary valuation drivers. Bicara Q2 2026 earnings call transcript
• Neutral Sentiment: Wells Fargo raised its price target from $16 to $23 but maintained an Equal Weight rating, highlighting disagreement among analysts about the stock’s risk-reward profile. A reported leadership shake-up also introduces some execution uncertainty as Bicara advances its development programs. Bicara leadership and milestone timeline
• Negative Sentiment: CEO Claire Mazumdar, COO Ryan Cohlhepp and CFO Ivan Hyep sold a combined 41,250 shares for approximately $1.15 million. The sales were made under pre-arranged Rule 10b5-1 plans, and the executives retained substantial holdings, but the cluster of insider sales can still pressure sentiment.

Insider Buying and Selling

In other Bicara Therapeutics news, CFO Ivan Hyep sold 28,000 shares of Bicara Therapeutics stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $28.85, for a total value of $807,800.00. Following the transaction, the chief financial officer owned 129,855 shares in the company, valued at $3,746,316.75. This trade represents a 17.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $28.98, for a total transaction of $817,641.72. Following the completion of the transaction, the chief operating officer owned 182,177 shares in the company, valued at approximately $5,279,489.46. This trade represents a 13.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 117,200 shares of company stock valued at $3,267,100. Insiders own 13.80% of the company's stock.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source